Stem Cell Study for Subjects With Congestive Heart Failure

Inclusion Criteria: * Subjects 21 to 80 years old (inclusive). * Subjects with functional class (NYHA) II or III ischemic heart failure. * Subjects who have attempted "best" cardiac medical therapy including long-acting nitrates, maximal use of beta-adrenergic blocking agents, and angiotensin-converting enzyme (ACE)inhibitors without control of symptoms. * Subjects must be identified as non-candidates for conventional revascularization by their referring cardiologist. * Subjects must have left ventricular ejection fraction \<40% by echocardiography. * All subjects must have a recent coronary angiogram (within the last 6 months) to document the coronary anatomy and insure the presence of coronary disease that is not amenable to standard revascularization procedures. * Have serum B-type Natriuretic Peptide (BNP) level \>100 pg/ml. Exclusion Criteria: * Myocardial infarction (Q wave or non-Q wave defined as CKMB \>3 times normal) within 30 days of treatment. * Successful coronary revascularization procedures within 3 months of study enrollment. * Documented stroke or transient ischemic attack (TIA) within 60 days of study enrollment. * NYHA Class IV heart failure and patients with idiopathic or non-ischemic heart failure. * History of severe aortic stenosis (aortic valve area \< 1.0 cm2) or insufficiency (\>2+); severe mitral stenosis (mitral valve area \<1.5 cm2); or severe mitral insufficiency(\>2+). * Implantation of biventricular pacemaker within 90 days of study treatment. * Severe co-morbidity associated with a reduction in life expectancy of less than 1 year, such as chronic medical illness (i.e. severe chronic obstructive pulmonary disease, renal failure or cancer).